Welcome to CDC stacks | Neurocognitive Outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study - 33351 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Neurocognitive Outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study
Filetype[PDF-833.50 KB]


Details:
  • Pubmed ID:
    22525956
  • Pubmed Central ID:
    PMC3337647
  • Description:
    Objective

    To assess neurocognitive outcomes following antipsychotic intervention in youth enrolled in the National Institute of Mental Health (NIMH)-funded Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS).

    Method

    Neurocognitive functioning of youth (ages 8–19 years) with schizophrenia or schizoaffective disorder was evaluated in a four-site randomized, double-blind clinical trial comparing molindone, olanzapine or risperidone. The primary outcomes were overall group change from baseline in neurocognitive composite and six domain scores after 8 weeks and continued treatment up to 52 weeks. Age and sex were included as covariates in all analyses.

    Results

    Seventy-seven of 116 TEOSS participants (66%) had post-baseline neurocognitive data. No significant differences emerged in the neurocognitive outcomes of the three medication groups. Therefore, the three treatment groups were combined into one group to assess overall neurocognitive outcomes. Significant modest improvements were observed in the composite score and in three of six domain scores in the acute phase, and in four of six domain scores in the combined acute and maintenance phases. Partial correlation analyses revealed very few relationships among Positive and Negative Syndrome Scale (PANSS) baseline or change scores and neurocognition change scores.

    Conclusions

    Antipsychotic intervention in youth with early-onset schizophrenia spectrum disorders (EOSS) led to modest improvement in measures of neurocognitive function. The changes in cognition were largely unrelated to baseline symptoms or symptom change. Small treatment effect sizes, easily accounted for by practice effects, highlight the critical need for the development of more efficacious interventions for the enduring neurocognitive deficits seen in EOSS.

  • Document Type:
  • Collection(s):
  • Funding:
    90DD043003/DD/NCBDD CDC HHS/United States
    M01-RR00037/RR/NCRR NIH HHS/United States
    MCJ379154A/PHS HHS/United States
    MH01-RR00046/MH/NIMH NIH HHS/United States
    P30 HD004147/HD/NICHD NIH HHS/United States
    R01 MH073801/MH/NIMH NIH HHS/United States
    R01 MH073967/MH/NIMH NIH HHS/United States
    U01 MH061355/MH/NIMH NIH HHS/United States
    U01 MH061355-01A1/MH/NIMH NIH HHS/United States
    U01 MH061464/MH/NIMH NIH HHS/United States
    U01 MH061464-01A1/MH/NIMH NIH HHS/United States
    U01 MH061528/MH/NIMH NIH HHS/United States
    U01 MH061528-04/MH/NIMH NIH HHS/United States
    U01 MH062726/MH/NIMH NIH HHS/United States
    U01 MH062726-01/MH/NIMH NIH HHS/United States
    U01MH61355/MH/NIMH NIH HHS/United States
    U01MH61464/MH/NIMH NIH HHS/United States
    U01MH61528/MH/NIMH NIH HHS/United States
    U01MH62726/MH/NIMH NIH HHS/United States
No Related Documents.
You May Also Like: